NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Belzutifan for treating tumours associated with von Hippel-Lindau disease

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

# Consultation

|  |
| --- |
| 1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how? |
| None identified. |

|  |
| --- |
| 1. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? |
| Yes, the patient experts highlighted that due to VHL being a genetic condition, some families are disproportionately affected. The condition can affect people when they are very young. People from deprived areas, with language, learning or cultural barriers, or those with disabilities may be at a disadvantage. The committee discussed the equality issues and agreed that its recommendations do not have a different impact on people protected by the equality legislation than on the wider population. The committee concluded that if belzutifan were recommended, the recommendation would not restrict access for some people over others. No other equality or social value judgement issues were identified. |

|  |
| --- |
| 1. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these? |
| No |

|  |
| --- |
| 1. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group? |
| No |

|  |
| --- |
| 1. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability? |
| No |

|  |
| --- |
| 1. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE’s obligations to promote equality? |
| No |

|  |
| --- |
| 1. Have the committee’s considerations of equality issues been described in the draft guidance, and, if so, where? |
| Yes, section 3.18 of the draft guidance. |

**Approved by Associate Director (name):** …Richard Diaz……………………

**Date:** 22/11/2023